Unlike naturally occurring GLP-1, pharmacologic GLP1-RA is resistant to degradation by the dipeptidyl peptidase 4 (DPP-4) enzyme, which leads to a longer half-life [4]. Here, DPP4 is linked to rheumatoid arthritis.